Related Experiment Video
Updated: Jan 10, 2026

Author Spotlight: Exploring Non-Motor Symptoms in Parkinson's Disease
Published on: September 22, 2023
Causal association between Parkinson disease, gut microbiota, and constipation: A Mendelian study
Jiamu Zheng1, Beibei Xu2, Lidan Gao3
1The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Abstract:
This study utilized multiple 2-sample Mendelian randomization (MR) approaches to evaluate the causal effects of gut microbiota on the risk of constipation and Parkinson disease (PD) and further investigated the mediating role of gut microbiota in the pathway linking PD to constipation. Two-sample MR analysis was conducted to identify gut microbiota with significant causal associations with constipation. These identified gut microbiota, along with PD, were incorporated as exposure variables into a MVMR framework. A comprehensive model encompassing gut microbiota, PD, and constipation was then established to perform mediation analysis, aiming to quantify the indirect effect of PD on constipation through gut microbiota. The 2-sample MR analysis identified statistically significant causal associations (P <.05) between specific gut microbiota and the development of constipation. Notable findings included c_Betaproteobacteria (OR = 0.899188), c_Methanobacteria (OR = 0.950024), f_Methanobacteriaceae (OR = 0.950024), g_Eubacterium rectale group (OR = 0.893372), and o_Methanobacteriales (OR = 0.950024). In the MVMR analysis, the association between PD and constipation was significant in Models 1 and 5 (P <.05). Mediation effect analysis revealed that the Eubacterium rectale group (g_Eubacterium rectale group) and Methanobacteriales (o_Methanobacteriales) exerted an indirect influence on the development of constipation through PD, with mediation effect proportions of 193.17% and 128.44%. This study revealed the potential causal effects of specific gut microbiota on constipation and, for the first time, proposed a mediating mechanism whereby PD indirectly influences constipation through certain gut microbiota. These findings provide novel insights into the complex relationships among PD, gut microbiota, and constipation, offering potential targets for gut microbiota-based interventions to address PD-associated constipation.
Insights
This study found specific gut bacteria causally influence constipation risk. Parkinson disease (PD) indirectly affects constipation through certain gut microbes, suggesting new therapeutic targets.
Area of Science:
- Microbiome research
- Neurogastroenterology
- Genetic epidemiology
Background:
- Constipation is a common issue, and its link with Parkinson disease (PD) is increasingly recognized.
- The gut microbiota's role in both PD and constipation is suspected but not fully elucidated.
- Understanding these complex interactions is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the causal relationship between gut microbiota and constipation risk.
- To examine the mediating role of gut microbiota in the association between PD and constipation.
- To identify specific microbial targets for potential interventions.
Main Methods:
- Utilized two-sample Mendelian randomization (MR) to assess causal effects of gut microbiota on constipation.
- Employed multivariable MR (MVMR) to analyze the interplay between PD, gut microbiota, and constipation.
- Conducted mediation analysis to quantify indirect effects of PD on constipation via gut microbiota.
Main Results:
- Identified specific gut bacteria, including c_Betaproteobacteria and g_Eubacterium rectale group, with significant causal effects on constipation.
- Confirmed a significant association between PD and constipation in the MVMR models.
- Demonstrated that the Eubacterium rectale group and Methanobacteriales mediate the effect of PD on constipation.
Conclusions:
- Specific gut microbiota have a causal impact on constipation development.
- Parkinson disease indirectly influences constipation through specific gut microbial pathways.
- These findings highlight the gut microbiota as a potential therapeutic target for managing constipation in PD patients.
More Related Videos
Related Concept Videos
Gastrointestinal Motility Disorders
Anatomy of the Intestines
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Pleiotropy

